The aim of present study was to formulate the sustained release floating tablets of Cephalexin (CPl) by direct compression method and optimized by Box-behnken response surface Methodology (rsM). a computer aided optimization technique was employed to investigate the formulation design by Boxbehnken rsM (design expert software version 8.0.7.1) to study the effect of the concentration of various polymer blends on the property of CPl gastroretentive floating tablets like floating lag time (Flt) and cumulative percent drug release (%Cdr). The independent variables investigated were polymeric concentrations (X1) and dependent variables were Flt (Y1), %Cdr (Y2) in 0.1n hCl (ph 1.2) buffer. results from precompression evaluation indicated that all the 17 and optimized formulation F18 were complied with the pharmacopoeial limits and post compression parameters were also gave satisfactory results. The predicted value for Flt and %Cdr obtained from software was compared with the experimental value of Flt and %Cdr of optimized formulation F18. It was observed that the obtained experimental results for optimized formulation were in very close agreement with the predicted values and also the optimized formulation gave good Flt and %Cdr when compared to the 17 formulations.
INTRODUCTION
Gastro retentive technology is playing a major role in revolutionizing the future of gastric retention in the pharmaceutical industry. The gastro retentive floating drug delivery system can be used as an alternative to conventional dosage forms for the class of drugs which undergoes intestinal or enzymatic degradation and generally, those drugs are acidic in nature (1) . drug absorption in the GI tract is a highly variable procedure and gastro retentive drug delivery systems prolong gastric retention of the dosage forms, extend the time for drug absorption thereby reduces drug wastage, improve bioavailability and solubility of drug which is less soluble in the high ph environment (2) . For gastric retention, floating drug delivery system is considered to be a potential approach and considerable research has been done on CPl floating tablets (3) (4) (5) (6) (7) .
CPl, a β-lactam antibiotic, is a broad-spectrum antibiotic for the treatment of wide variety of bacterial infections, including urinary tract infections and respiratory tract infections (3). It is a lipophilic weak acid with pKa values of 4.5 and is stable in gastric conditions but degrades in intestinal conditions, hence a gastro retentive dosage form would be essential to ensure better drug delivery (4) . CPl has higher absorption in proximal region of the gastrointestinal tract and lesser bioavailability (35%) mainly due to its instability in intestine and its narrow absorption window at the upper GI tract (5) . This suggests that CPl is an ideal candidate for gastro retentive drug delivery system which prolongs the gastric residence time of the drug, providing prolonged drug release in upper gastro intestinal tract, where absorption of CPl is well confined.
The main objective of the present study was to formulate and optimize the sustained release gastro retentive floating tablets of CPl by direct compression method using Box-behnken response surface methodology.
MATERIALS AND METHODS

Materials
CPl was purchased from Orchid Chemicals and Pharmaceuticals ltd., India. hydroxy Propyl Methyl Cellulose (hPMC K4M) obtained from strides acrolabs, India, Cetyl alcohol (Ca) from loba chemie, India, sodium Carboxy Methyl Cellulose (sCMC) from Fisher scientific, India, Microcrystalline cellulose (MCC) from rolex chemical industries, India, sodium lauryl sulphate (sls) and sodium bicarbonate (sBC) from Yarrow chemicals, India, talc and Magnesium stearate (Ms) from s.d. Fine chem., India.
FTIR studies
The drug-excipients compatibility was determined by KBr disc (pellet) method using FtIr spectrophotometer (Bruker, usa). The discs of pure drug and its physical mixtures were prepared and scanned from 4000 to 400 cm -1 . The obtained spectra of pure drug and spectra of its physical mixtures were compared to know the possible drug-excipients interactions.
Experimental design of floating tablets of CPL
The factors like hPMC K4M, Ca and sBC were identified as critical formulation factors based on their effect or role on final dosage form from existing studies (3-7) and any variation in those factors shows a variable response on the dosage form. hence, the careful optimization of these factors is essential to obtain a better response of the developed dosage form. In the present investigation, independent formulation variables evaluated were X1: Polymeric concentrations and dependent variables investigated were Y1: Flt in 0.1n hCl (ph 1.2), Y2: % drug release in 0.1n hCl (ph 1.2) buffer at the end of 8 h. seventeen different formulation batches of floating tablets were evaluated to determine the potential effect of those independent variables on dependent variables (8) . From the existing works, the minimum and maximum effective concentrations of those variables were entered into the software; thereby it was designed 17 formulations with different polymeric concentrations (table 1). F2  F3  F4  F5  F6  F7  F8  F9  F10  F11  F12  F13  F14  F15  F16  F17   CPl  250  250  250  250  250  250  250  250  250  250  250  250  250  250  250  250  250   hPMC K4M 145  145  135  135  145  145  135  155  135  145  145  145  155  145  155  155  145   Ca  40  50  50  40  40  40  40  30  30  30  40  50  40  40  40  50  30   sBC  40  30  40  30  40  40  50  40  40  30  40  50  50  40  30  40  50   sCMC  35  35  35  35  35  35  35  35  35  35  35  35  35  35  35  35 
Preparation of CPL floating tablets
tablets containing 250 mg of CPl were prepared according to the design depicted in table 1 by direct compression method. The excipients were chosen after the comprehensive drug excipient interaction studies and those were namely release retarding polymer (s) like hPMC K4M, Ca and sCMC, sBC (gas generating agent), sls and MCC (filler) were passed through sieve no.60, separately. Mixing of the ingredients was carried out by using a mortar and pestle for 10 min. lubricant (Magnesium stearate) and glidant (talc) previously passed through sieve no. 60 were added to the mixture and mixing was continued for additional 5 min. Finally, 550 mg of each mixture was weighed and fed manually in to the die of a 10 station tablet punching machine using 12 mm round shaped punches to produce the required tablets (rIMeK rotary tablet Punching machine, India). The hardness was adjusted to 7 kg/cm 2 .
Evaluation studies
Precompression evaluation studies
The powder blends were evaluated for the precompression parameters like bulk density, tapped density, compressibility index (Carr's Index), hausner's ratio and angle of repose (9-10).
Post compression evaluation studies
The tablets were evaluated for finished product quality control tests like thickness, weight variation, hardness, friability and drug content uniformity (11-12).
Tablet floating behavior
The floating behavior of the tablets was visually determined in triplicate, according to the Flt method. Briefly, a tablet was placed in a glass beaker containing 100 ml of 0.1n hCl (ph 1.2) and maintained in a water bath at 37±0.5ºC, thereby the floating time was measured (13-14).
Swelling studies
The extent of swelling is measured in terms of % of weight gained by the tablet. One tablet from each formulation was weighed (w 1 ) and kept in glass beaker containing 100 ml of 0.1n hCl (ph 1.2) buffer. at the end of the specified time intervals, tablets were withdrawn from the glass beaker and therefore the excess buffer was blotted with the tissue paper by taking care to avoid the surface erosion from tablet and swollen tablet was then reweighed (w 2 ) (15). The % of weight gained by the tablet was calculated by using following formula as.
In-vitro dissolution studies
In-vitro dissolution study of CPl was performed using usP dissolution apparatus, type II (Paddle method) (lab India 8 basket dissolution apparatus, India) at 37ºC ± 0.5ºC and the paddle was set to rotate at a speed of 50 rpm. The tablets were placed in the dissolution apparatus containing 900 ml of 0.1n hCl (ph 1.2) buffer as dissolution medium. samples were withdrawn (10 ml) and replaced with an equal amount of fresh dissolution medium at particular time intervals, samples were immediately filtered through whatmann filter paper and diluted with the dissolution media. The absorbances of these diluted samples were noted at λmax 256 nm using uV-Visible spectrophotometer (lab India 1700 uV-Visible spectrophotometer, India) (16-17).
Kinetics studies
The release kinetics of the drug was described by fitting the obtained in-vitro dissolution data into various kinetic models like zero order, first order, higuchi's and Korsmeyer-Peppas models (18) (19) .
RESULTS AND DISCUSSION
FTIR Studies
FtIr spectrum of pure drug and its physical mixtures were studied. The major Ir peaks observed for pure CPl at 1758.22, 3272.98, 1689.58, 1454.85 and 1594.85 cm -1 were mainly because of C=O stretching, n-h stretching, C=O stretching, C=C stretching and n-h bending respectively. In the present study, it was observed that there were no major shifts in its individual characteristic peaks; hence, it indicates that there were no incompatibility issues between drug and polymers used (Figure 1 ).
Precompression evaluation
The powder blends of formulations F1-F17 have the bulk 
Post compression evaluation
weight variation test revealed that all the formulations [F1-F17] developed in the formulation development phase were complied with the official limits (if the tablet weight is greater than 324 mg, the maximum difference allowed is ±10 mg) and ranged from 550.333±0.288 mg to 551±0.5 mg. hardness of all the formulations was ranged from 6.65±0.060 kg/cm 2 to 6.943±0.260 kg/cm 2 and thickness ranged from 4.46±0.026 to 4.496±0.050 mm. The ideal friability value is less than 1% and the obtained experimental values were ranged from 0.427±0.082 % to 0.894±0.016 %, hence the friability test was satisfied. The maximum difference allowed for drug content is ±5 and it was ranged from 97.254±1.113% to 99.999±4.043% (table 3) .
Floating behavior
On immersion in 0.1 n hCl (ph 1.2) at 37 ºC, it expands and CO 2 was formed within the tablets thereby floated and remained buoyant without disintegration. Formulations consists of high concentration of hPMC K4M (F-8) showed good Flt and tFt, which might be due to the rapid hydration of the polymer, thereby it forms gelatinous layer when exposed to aqueous medium. This gelatinous layer prevents the escape of CO 2 from dosage form thereby decreases the density which leads to floating of tablets within a short period of time (table 3) (19). all the results were expressed in mean ± sd (n=3)
Swelling study
The swelling index was calculated with respect to the time and results were represented in table 4. as the time increases, the swelling index was also increased, because weight gain by tablet was increased proportionally with rate of hydration. later on, it decreased gradually due to dissolution of outermost gelled layer of the tablet into dissolution medium (20) . water uptake studies showed that the formulation with higher percentage of hPMC K4M imbibed more water and was swollen to greater extent than formulation with low percentage of hPMC K4M. swelling index of all the formulations increased upto 6 th h and subsequently it was decreased at 8 th h. The swelling index of the formulation F8 was found to be maximum throughout the study (table  14) . The swelling index of all the formulations is increases with increase in the concentration of hPMC K4M and decreases with increase in the concentration of Ca due to its hydrophobic nature (21) . Incorporation of varying amounts of sBC in the formulation had shown no significant impact on the swelling index. Formulations (F3, F4, F7 and F9) with low concentration of hPMC K4M swelled instantly which did not persist due to subsequent erosion which was supported by the kinetic studies where the r 2 value was better to the higuchi model except F9. all the results were expressed in mean ± sd (n=3)
In-vitro drug release studies
From the release profiles, it was concluded that the variation in concentrations of polymer from F1 to F17 had variable effect on drug release. The effect of hPMC K4M and Ca could be observed at constant sCMC level. hPMC K4M with higher molecular weight forms gel of higher viscosity (4000cps) compared to sCMC (not less than 2000cps). Formulations containing lower limit of hPMC K4M showed early release in dissolution medium but as increase in the concentration of Ca causes decrease in the drug release due to its water repelling capacity and the formulation F9 showed maximum drug release of 96.35% (table 5) . all the results were expressed in mean ± sd (n=3) all the results were expressed in mean ± sd (n=3) F5-F11, F14 and F17, the r 2 value of zero order is very near to one than other kinetic models. Thus, it can be said that the drug release follows zero-order kinetics. The r 2 value of formulations F3, F12, F13, F15 and F16 was found to very near to one and they follow First order kinetics. The 'n' values of Korsmeyer-Peppas model of the formulations (F1, F2 and F4-F17) have the 'n' value in the range of 0.45-0.89, thus they follow the non-Fickian transport and the 'n' value of formulation F-3 is below 0.45 which indicates the Fickian transport (table 6).
In-vitro drug release kinetics
The mechanism of drug release for the dissolution data was determined by finding the r 2 value for each kinetic model viz. zero order, first order, higuchi's, and KorsmeyerPeppas models. For tablets, an 'n' value near to 0.45 indicates diffusion controlled drug release and an 'n' value 0.89 or near to 1 indicates swelling-controlled drug release. The intermediate values of n between 0.45 and 1 can be regarded as an indicator for both the phenomena (anomalous transport). For the formulations F1, F2, F4, 
Formulation development
In the development of any pharmaceutical formulation, a very important issue is to design a formulation with the optimized quality. The rsM has been ordinarily used for the designing and optimization of the various pharmaceutical formulations, which needs minimum experimentation. Thus, it is less time consuming and cost effective than the other typical ways of formulating the dosage forms. Based on the design of experiments, rsM encompasses the generation of polynomial equations of the response over the experimental domain to determine the optimum formulation(s). a computer aided optimization technique was employed to investigate the formulation design by using Box-behnken design expert software version 8.0.7.1. and studies the effect of concentration of various polymer blends used on the properties like floating lag time (Flt), cumulative percent drug release (%Cdr) of CPl gastroretentive floating tablets.
Optimization
The Flt and %Cdr data (table 17) was entered into the generated design model and then the software generates model graphs to interpret and evaluate the given data to find out the best response. response 1 (Flt in 0.1n (ph 1.2) hCl) and 2 (%Cdr in 0.1n (ph 1.2) hCl) were analyzed by anOVa for response surface linear Model-1 and 2 respectively.
Response 1: FLT in 0.1N HCl (pH 1.2)
The Model F-value of 39.24 implies the model is significant. There is only a 0.01% chance that a "Model F-Value" could occur in large due to noise.
Response 2: %CDR in 0.1N HCl (pH 1.2)
The Model F-value of 40.51 implies the model is significant. There is only a 0.01% chance that a "Model F-Value" could occur in large due to noise. all responses were fitted to linear models as suggested by design expert software 8.0.7.1. The F value for Flt, %Cdr were found to be 39.24, 40.51 respectively indicating that the models are significant. The values of Prob ˃ F were found to be < 0.0001 for all responses indicating that the models are significant (table 7) . The contour and response surface plots for all responses of all formulation factors are shown in figure 2 . with the help of these 3d and contour graphs, the point at which maximum predicted response shown was recorded. with the help of factors tool, the concentrations of critical factors were adjusted in the software to show the maximum predicted response (table 8) . 
Point Prediction and optimization results
to optimize all the responses with different targets, a multicriteria decision approach (a numerical optimization technique by the desirability function and a graphical optimization technique by the overlay plot) was used. The optimized formulation was obtained by applying constrains on dependent variable responses and independent variables. Constrains were Flt in 0.1n (ph 1.2) hCl; % Cdr at 8 h and these constrains are common for all the formulations.
The recommended concentrations of the independent variables were calculated by the design expert software from the above plots which has the highest desirability near to 1.0. The predicted concentrations of critical factors (hPMC K4M-136.08 mg, Ca-30.11 mg, sBC-49.57 mg) generated by software showed the Flt of 7.856 sec and drug release of 99.15% (table 8) . Based on these predictions, an optimized formulation has been prepared with the predicted variable factors and analyzed for the %Cdr and Flt.
CONCLUSION
From the experimental data, it could be concluded that a successful gastro retentive floating drug delivery system for CPl has been developed by direct compression method using Box-behnken rsM. statistically optimized formulation containing CPl showed promising results and there exist a scope for in-vivo evaluation using suitable animal models and increase in bioavailability may be confirmed.
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Evaluation and validation of the optimized formulation
By taking the predicted factors into consideration, a formulation has been developed. The prepared formulation was evaluated for the precompressional and post compressional parameters. Precompression parameters like angle of repose, hausner's ratio and Carr's index were found to be within the prescribed limits. Post compressionl parameters like the weight variation, thickness, drug content, swelling index, Flt, In-vitro dissolution studies were also studied. The tablets produced with the predicted concentrations of critical factors showed drug release of 97.691% in 8 h and Flt of 8.041 sec (table 9) and the results are in very close agreement with the model predictions. drug release from the optimized formulation F18 followed zero order release (r 2 = 0.916) with non-fickian type of diffusion mechanism (n=0.505). The relative error (%) between the predicted and experimental values confirms the predictability and validity of the model. 
